Association between gross domestic product (GDP) per capita and the total number of essential diabetes medicines selected on their NEML by each country in the study.

<p>Association between gross domestic product (GDP) per capita and the total number of essential diabetes medicines selected on their NEML by each country in the study.</p

Association between relative burden of diabetes in countries and the total number of essential diabetes medicines selected on their NEML by each country in the study.

<p>Association between relative burden of diabetes in countries and the total number of essential diabetes medicines selected on their NEML by each country in the study.</p

Inclusion of diabetes medications in the NEMLs of low and middle income countries (n = 32).

<p>Inclusion of diabetes medications in the NEMLs of low and middle income countries (n = 32).</p

Number of selected essential medicines for diabetes on NEMLs in different geographical regions and across different income levels.

<p>*: p values were 0.386, 0.663, 0.865 across different WHO regions and 0.008, 0.008, 0.018 across different income levels for the number of essential medicines for diabetes, number of “Insulin and analogues” and number of “Oral blood glucose lowering” medicines, respectively.</p><p>Number of selected essential medicines for diabetes on NEMLs in different geographical regions and across different income levels.</p

Examples of non-compliance per key criteria from the disease awareness campaigns.

<p>Examples of non-compliance per key criteria from the disease awareness campaigns.</p

Median availability of any product type (originator brand/generic) of essential and non-essential medicines by ATC categories.

<p>*Ectoparasiticides, including scabicides, insecticides and repellents, **Anti-inflammatory and anti-rheumatic products, ***Agents acting on the renin-angiotensin system.</p

Countries and surveys included in the study.

<p>*As at the time of the survey. LIC: low income country, LMIC: lower middle income country, UMIC: upper middle income country.</p><p>**Data is closest to the year of the survey.</p>†<p>2003–2005.</p

Overlap between relevant provisions within the WHO Ethical Criteria for Medicinal Drug Promotion and the CGR Guidelines for provision of information on prescription medicines.

<p>Overlap between relevant provisions within the WHO Ethical Criteria for Medicinal Drug Promotion and the CGR Guidelines for provision of information on prescription medicines.</p

Material Characteristics.

<p>* RR calculated by adding 0.5 to all cells.</p><p>Material Characteristics.</p

Median availability of surveyed medicines.

<p>IQR = interquartile range.</p